BIOMARIN PHARMACEUTICAL INC (BMRN) Stock Fundamental Analysis
NASDAQ:BMRN - US09061G1013 - Common Stock
58.58 USD
+0.51 (+0.88%)
58.58 USD
0 (0%)
BMRN gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 549 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making BMRN a very profitable company, without any liquidiy or solvency issues. BMRN scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings could make BMRN a good candidate for value and quality investing.
1. Profitability
1.1 Basic Checks
BMRN had positive earnings in the past year.
In the past year BMRN had a positive cash flow from operations.
BMRN had positive earnings in 4 of the past 5 years.
In the past 5 years BMRN always reported a positive cash flow from operatings.
1.2 Ratios
BMRN's Return On Assets of 8.81% is amongst the best of the industry. BMRN outperforms 93.26% of its industry peers.
BMRN's Return On Equity of 10.90% is amongst the best of the industry. BMRN outperforms 93.26% of its industry peers.
BMRN's Return On Invested Capital of 10.27% is amongst the best of the industry. BMRN outperforms 94.17% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BMRN is significantly below the industry average of 16.25%.
The 3 year average ROIC (3.73%) for BMRN is below the current ROIC(10.27%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.81% | ||
| ROE | 10.9% | ||
| ROIC | 10.27% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
1.3 Margins
BMRN has a better Profit Margin (21.45%) than 94.90% of its industry peers.
BMRN has a Operating Margin of 27.07%. This is amongst the best in the industry. BMRN outperforms 96.17% of its industry peers.
BMRN has a Gross Margin of 79.56%. This is amongst the best in the industry. BMRN outperforms 84.70% of its industry peers.
BMRN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.07% | ||
| PM (TTM) | 21.45% | ||
| GM | 79.56% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
2. Health
2.1 Basic Checks
BMRN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, BMRN has more shares outstanding
The number of shares outstanding for BMRN has been increased compared to 5 years ago.
BMRN has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 6.05 indicates that BMRN is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 6.05, BMRN is doing good in the industry, outperforming 78.69% of the companies in the same industry.
BMRN has a debt to FCF ratio of 0.86. This is a very positive value and a sign of high solvency as it would only need 0.86 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 0.86, BMRN belongs to the best of the industry, outperforming 95.08% of the companies in the same industry.
A Debt/Equity ratio of 0.10 indicates that BMRN is not too dependend on debt financing.
BMRN has a Debt to Equity ratio of 0.10. This is in the lower half of the industry: BMRN underperforms 63.93% of its industry peers.
Even though the debt/equity ratio score it not favorable for BMRN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.86 | ||
| Altman-Z | 6.05 |
ROIC/WACC1.08
WACC9.47%
2.3 Liquidity
BMRN has a Current Ratio of 5.56. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of BMRN (5.56) is comparable to the rest of the industry.
BMRN has a Quick Ratio of 3.60. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of BMRN (3.60) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.56 | ||
| Quick Ratio | 3.6 |
3. Growth
3.1 Past
BMRN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 139.01%, which is quite impressive.
The Revenue has grown by 18.36% in the past year. This is quite good.
BMRN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.86% yearly.
EPS 1Y (TTM)139.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%119.64%
Revenue 1Y (TTM)18.36%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%15.92%
3.2 Future
The Earnings Per Share is expected to grow by 28.47% on average over the next years. This is a very strong growth
BMRN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.65% yearly.
EPS Next Y57.89%
EPS Next 2Y41.83%
EPS Next 3Y33.62%
EPS Next 5Y28.47%
Revenue Next Year12.45%
Revenue Next 2Y10.9%
Revenue Next 3Y9.72%
Revenue Next 5Y7.65%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 17.38, the valuation of BMRN can be described as rather expensive.
Based on the Price/Earnings ratio, BMRN is valued cheaply inside the industry as 95.08% of the companies are valued more expensively.
BMRN is valuated rather cheaply when we compare the Price/Earnings ratio to 27.24, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 13.18, which indicates a correct valuation of BMRN.
BMRN's Price/Forward Earnings ratio is rather cheap when compared to the industry. BMRN is cheaper than 96.17% of the companies in the same industry.
BMRN's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 35.82.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.38 | ||
| Fwd PE | 13.18 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BMRN indicates a rather cheap valuation: BMRN is cheaper than 96.36% of the companies listed in the same industry.
95.99% of the companies in the same industry are more expensive than BMRN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.27 | ||
| EV/EBITDA | 11.17 |
4.3 Compensation for Growth
BMRN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BMRN has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as BMRN's earnings are expected to grow with 33.62% in the coming years.
PEG (NY)0.3
PEG (5Y)N/A
EPS Next 2Y41.83%
EPS Next 3Y33.62%
5. Dividend
5.1 Amount
No dividends for BMRN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
58.58
+0.51 (+0.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners99.84%
Inst Owner Change-0.36%
Ins Owners0.66%
Ins Owner Change9%
Market Cap11.25B
Analysts82.86
Price Target98.8 (68.66%)
Short Float %2.71%
Short Ratio2.29
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)37.96%
Min EPS beat(2)31.48%
Max EPS beat(2)44.44%
EPS beat(4)4
Avg EPS beat(4)24.64%
Min EPS beat(4)4.22%
Max EPS beat(4)44.44%
EPS beat(8)6
Avg EPS beat(8)18.75%
EPS beat(12)9
Avg EPS beat(12)-3.48%
EPS beat(16)13
Avg EPS beat(16)0.88%
Revenue beat(2)1
Avg Revenue beat(2)2.55%
Min Revenue beat(2)-1.37%
Max Revenue beat(2)6.48%
Revenue beat(4)3
Avg Revenue beat(4)3.05%
Min Revenue beat(4)-1.37%
Max Revenue beat(4)6.48%
Revenue beat(8)4
Avg Revenue beat(8)1.05%
Revenue beat(12)5
Avg Revenue beat(12)0.21%
Revenue beat(16)7
Avg Revenue beat(16)-0.31%
PT rev (1m)1.4%
PT rev (3m)0.84%
EPS NQ rev (1m)-20.77%
EPS NQ rev (3m)-24.97%
EPS NY rev (1m)-0.88%
EPS NY rev (3m)0.95%
Revenue NQ rev (1m)-1.38%
Revenue NQ rev (3m)-0.64%
Revenue NY rev (1m)0.94%
Revenue NY rev (3m)0.94%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.38 | ||
| Fwd PE | 13.18 | ||
| P/S | 3.67 | ||
| P/FCF | 16.27 | ||
| P/OCF | 14.67 | ||
| P/B | 1.87 | ||
| P/tB | 2.01 | ||
| EV/EBITDA | 11.17 |
EPS(TTM)3.37
EY5.75%
EPS(NY)4.45
Fwd EY7.59%
FCF(TTM)3.6
FCFY6.14%
OCF(TTM)3.99
OCFY6.82%
SpS15.96
BVpS31.39
TBVpS29.12
PEG (NY)0.3
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.81% | ||
| ROE | 10.9% | ||
| ROCE | 12.25% | ||
| ROIC | 10.27% | ||
| ROICexc | 13.02% | ||
| ROICexgc | 14.18% | ||
| OM | 27.07% | ||
| PM (TTM) | 21.45% | ||
| GM | 79.56% | ||
| FCFM | 22.56% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
ROICexc(3y)4.34%
ROICexc(5y)N/A
ROICexgc(3y)4.77%
ROICexgc(5y)N/A
ROCE(3y)4.44%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
F-Score7
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.86 | ||
| Debt/EBITDA | 0.65 | ||
| Cap/Depr | 90.83% | ||
| Cap/Sales | 2.47% | ||
| Interest Coverage | 93.49 | ||
| Cash Conversion | 84.01% | ||
| Profit Quality | 105.16% | ||
| Current Ratio | 5.56 | ||
| Quick Ratio | 3.6 | ||
| Altman-Z | 6.05 |
F-Score7
WACC9.47%
ROIC/WACC1.08
Cap/Depr(3y)111.01%
Cap/Depr(5y)114.82%
Cap/Sales(3y)4.71%
Cap/Sales(5y)5.6%
Profit Quality(3y)57.85%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)139.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%119.64%
EPS Next Y57.89%
EPS Next 2Y41.83%
EPS Next 3Y33.62%
EPS Next 5Y28.47%
Revenue 1Y (TTM)18.36%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%15.92%
Revenue Next Year12.45%
Revenue Next 2Y10.9%
Revenue Next 3Y9.72%
Revenue Next 5Y7.65%
EBIT growth 1Y198.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year99.59%
EBIT Next 3Y41.32%
EBIT Next 5Y23.56%
FCF growth 1Y1589.89%
FCF growth 3Y36.9%
FCF growth 5YN/A
OCF growth 1Y375.67%
OCF growth 3Y23.45%
OCF growth 5Y63.99%